Examination of mechanism and the skin physiology change regarding the anti-inflammation action of minocycline in the skin disorders of the epithelium growth factor receptor inhibitor

Not Applicable

Completed

• Conditions: ung cancer(adenocarcinoma) Skin disorder(acneiform eruption)

• Registration Number: JPRN-UMIN000024256
• Lead Sponsor: Wakayama medical university Third department of internal medicine,Oncology center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-03
• Study Completion: 2018-11-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1)The patient with history of the EGFR inhibitor treatment. 2)The patient who applied steroid ointment and retinoid or a drug having retinoid-like action to the skin part that was measurement subject within two weeks before clinical trial start. 3)The patient who takes steroid and the minocycline internal use. 4)Complications of a wide range of skin or the patient who has the past. (burn, psoriasis, scleroderma etc.) 5)The patient who received drug-caused skin eruption within two weeks before clinical trial start. 6)A patient with the past of sensitivity to heparin resemblance material component preparation. 7)A patient with hemorrhagic blood disorder(hemophilia, more than grade3 thrombocytopenia, purpura) 8)The patient that it is expected that a few bleeding causes a serious result. 9)A case having serious complications(liver damages more than grade2, renal damage etc.). 10)The patient who internal use is difficult, and has severe diarrhea (more than grade2). 11)The patient with overlap cancer of the activity. 12)A nursing girl and the patient who may be pregnant. The patient who judges that a clinical study doctor (clinical study responsibility doctor,) is inadequate for reasons of others.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examination of the mechanism of the anti-inflammatory effect of the minocycline and the pathophysiology of the dermatopathy of EGFR-TKI in biopsy specimens

Secondary Outcome Measures

Name	Time	Method
Examination of biomarker of the dermatopathy by a skin physiologic change. Quantification of cytokine and severity(CTCAE ver.4) of the anti-inflammatory effect of the minocycline. Safety after the minocycline internal use. Examination of an effect of EGFR-TKI and skin toxicity.